Metvix PDT in acne: New study published in British Journal of Dermatology
Oslo, Norway, 7 February 2006
Results of an investigator initiated study of methyl aminolevulinate (Metvix®) photodynamic therapy are now posted on the Online Early web pages of the British Journal of Dermatology. The study was performed at Bispebjerg Hospital, University of Copenhagen with Professor Hans Chr. Wulf as the main investigator.
The study is a blinded, randomized, and controlled trial comparing Metvix PDT to an untreated control group for the treatment of moderate to severe facial acne in 36 patients with acne. The results showed a 68% reduction in inflammatory lesions in the Metvix group, and no change in the control group. Side effects included pain and erythema. The authors conclude that Metvix PDT is an efficacious treatment for acne, but that the treatment regimen should be optimized to reduce the side effects.
Dr. Kjetil Hestdal, President and CEO of PhotoCure, comments: "We are pleased to see that the results of this investigator driven study confirm the efficacy results from our own pilot study reported in 2005. We are currently working on our development plans for this indication."
Acne is a common skin condition which affects up to 85% of adolescents. Of those who seek medical advice, about 50% have moderate and 20% have severe acne. Current therapies for these patients include oral antibiotics and isotretinoin, both products that may have significant adverse effects. There is thus a clear medical need for a safe and efficacious topical treatment for acne patients.